Entyvio

Chemical Namevedolizumab
Dosage FormInjection (intravenous; 300mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyTakeda Pharmaceuticals America, Inc
Approval Year2014

Indication

  • For adult patients with moderately to severely active Ulcerative Colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
  • For adult patients with moderately to severely active Crohn’s Disease who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Entyvio (vedolizumab) Prescribing Information2014Takeda Pharmaceuticals America, Inc., Deerfield, IL
Document TitleYearSource
Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis.2020Clinical Gastroenterology and Hepatology
Biologics for inflammatory bowel disease and their safety in pregnancy: A systematic review and meta-analysis.2020Clinical Gastroenterology and Hepatology
Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: A systematic review. 2019Journal of Crohn’s and Colitis
Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. 2019Alimentary Pharmacology & Therapeutics
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. 2019Scandinavian Journal of Gastroenterology
Safety of vedolizumab in liver transplant recipients: A systematic review.2019United European Gastroenterology Journal
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.2018The Cochrane Database of Systematic Reviews
Systematic Review and Meta-Analysis: Preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease.2018Journal of Crohn's and Colitis
Primary non-response to tumor necrosis factor antagonists is associated with Inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis.2018Journal of Crohn's and Colitis
Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease.2018Inflammatory Bowel Diseases
Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis. 2017Alimentary Pharmacology & Therapeutics
Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials.2017Alimentary Pharmacology & Therapeutics
Vedolizumab compared with certolizumab in the therapy of crohn disease: A systematic review and indirect comparison. 2016Pharmacotherapy
Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.2016Alimentary Pharmacology and Therapeutics
Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis.2016PLoS One